Evidence map›Paper›PMID 33063185›Full record

ArticleEuropean radiology2021

Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies.

Lynn J Savic, Julius Chapiro, Eliot Funai, Khaled Bousabarah, Isabel T Schobert, Edvin Isufi, Jean-Francois H Geschwind, Sophie Stark, Ping He, Michelle A Rudek and 4 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02753881 (Pharmacokinetics of Doxorubicin in Conventional Transarterial Chemoembolization), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02753881 phase1completednot on this map

Pharmacokinetics of Doxorubicin in Conventional Transarterial Chemoembolization (cTACE) of Primary and Secondary Liver Cancer

TypeinterventionalSponsorYale UniversityRan2015 to 2019Enrolled30ConditionsLiver CancerArmswhole liver lobe cTACE doxorubicin, superselective cTACE doxorubicin
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Lynn J SavicDepartment of Radiology and Biomedical Imaging, Division of Interventional Radiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Julius ChapiroDepartment of Radiology and Biomedical Imaging, Division of Interventional Radiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Eliot FunaiDepartment of Radiology and Biomedical Imaging, Division of Interventional Radiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Khaled BousabarahDepartment of Stereotactic and Functional Neurosurgery, University Hospital of Cologne, Cologne, Germany.
Isabel T SchobertDepartment of Radiology and Biomedical Imaging, Division of Interventional Radiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Edvin IsufiDepartment of Radiology and Biomedical Imaging, Division of Interventional Radiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Jean-Francois H GeschwindPreScience Labs/Cage Pharma, Westport, CT, USA.
Sophie StarkDepartment of Radiology and Biomedical Imaging, Division of Interventional Radiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Ping HeSidney Kimmel Comprehensive Cancer Center at Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Michelle A RudekSidney Kimmel Comprehensive Cancer Center at Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Juan Carlos Perez LozadaDepartment of Radiology and Biomedical Imaging, Division of Interventional Radiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Rajasekhara AyyagariDepartment of Radiology and Biomedical Imaging, Division of Interventional Radiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Jeffrey PollakDepartment of Radiology and Biomedical Imaging, Division of Interventional Radiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA.
Todd SchlachterDepartment of Radiology and Biomedical Imaging, Division of Interventional Radiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06520, USA. todd.schlachter@yale.edu.ORCID http://orcid.org/0000-0002-4483-7422
Yale University · USJohns Hopkins University · USUniversity Hospital Cologne · DE

Funding

Guerbet Institutional Study Grant
6 · The paper itself

Abstract

objectivesTo evaluate the prognostic potential of Lipiodol distribution for the pharmacokinetic (PK) profiles of doxorubicin (DOX) and doxorubicinol (DOXOL) after conventional transarterial chemoembolization (cTACE).

methodsThis prospective clinical trial ( ClinicalTrials.gov : NCT02753881) included 30 consecutive participants with liver malignancies treated with cTACE (5/2016-10/2018) using 50 mg DOX/10 mg mitomycin C emulsified 1:2 with ethiodized oil (Lipiodol). Peripheral blood was sampled at 10 timepoints for standard non-compartmental analysis of peak concentrations (C

resultsHepatocellular (n = 26), cholangiocarcinoma (n = 1), and neuroendocrine metastases (n = 3) were included. Stratified according to Lipiodol distribution, DOX-C

conclusionsThis prospective clinical trial provides updated PK data revealing Lipiodol distribution as an imaging marker predictive of DOX-C KEY POINTS: • Prospective pharmacokinetic analysis after conventional TACE revealed Lipiodol distribution (1 vs. ≥ 2 segments vs. lobar) as an imaging marker predictive of doxorubicin peak concentrations (C

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsDoxorubicinEthiodized OilHumansProspective StudiesTreatment OutcomeDoxorubicinEthiodized OilBiomarkers, cancerDoxorubicinLipiodolLiver cancerPharmacokinetics

Identifiers

PMID33063185
OpenAlexW3092659087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.